Ronald Collazo Pagan, MD
Internal Medicine · Manati, PRNPI 1194958041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,900 of the $206,432 with a category attached, or 68.3%. Viiv Healthcare Company accounts for 71.6% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $74,961, 3.7 times the $20,165 reported in 2019. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $657.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$148K
- Johnson & Johnson$31K
- Gilead$11K
- Merck$9K
- Janssen Products, LP$7K
- Hologic Sales And Service, LLC$72
- plus $141 from 6 others
What the payments were for
- Consulting fees$26,02013%
- Speaking & faculty fees$140,90068%
- Travel & lodging$30,31115%
- Food & beverage$9,1644%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 180 | $147,823 |
| Johnson & Johnson | 50 | $31,126 |
| Gilead | 32 | $10,867 |
| Merck | 26 | $9,384 |
| Janssen Products, LP | 18 | $7,018 |
| Hologic Sales And Service, LLC | 1 | $72 |
| Pfizer Pharmaceuticals LLC | 1 | $34 |
| AstraZeneca | 2 | $33 |
| Exact Sciences | 1 | $25 |
| Novartis | 1 | $22 |
| AbbVie | 1 | $15 |
| Theratechnologies Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$206,432 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $187,200 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 23 | $89,503 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 16 | $74,591 |
| DescovyEmtricitabine/Tenofov Alafenam | 19 | $54,349 |
| TivicayDolutegravir Sodium | 22 | $54,060 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $51,873 |
| JardianceEmpagliflozin | 24 | $35,047 |
| EliquisApixaban | 40 | $32,492 |
| PifeltroDoravirine | 12 | $20,981 |
| TrulicityDulaglutide | 18 | $19,544 |
| SynthroidLevothyroxine Sodium | 172 | $18,774 |
| FarxigaDapagliflozin Propanediol | 19 | $17,098 |
| OzempicSemaglutide | 15 | $14,962 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $14,328 |
| MyrbetriqMirabegron | 11 | $11,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $10,867 | $293,42169 claims |
| Janssen Products, LPSymtuza | $7,018 | $74,59116 claims |
| Viiv Healthcare CompanyTivicay | $147,823 | $54,06022 claims |
| MerckPifeltro, Janumet Xr | $9,384 | $35,30924 claims |
| AstraZenecaFarxiga, Symbicort | $33 | $20,01031 claims |
| AbbVieSynthroid | $15 | $18,774172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Manati
- Rafael PerezManati$18K
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Angel VinuelaDorado$182K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Luis Rivera ColonRio Piedras$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.